Plasma Isoflavones and Fibrocystic Breast Conditions and Breast Cancer Among Women in Shanghai, China

Lampe, Johanna W.; Nishino, Yoshikazu; Ray, Roberta M.; Wu, Chunyuan; Li, Wenjin; Lin, Ming-Gang; Gao, Dao Li; Hu, Yongwei; Shannon, Jackilen; Stalsberg, Helge; Porter, Peggy L.; Frankenfeld, Cara L.; Wähälä, Kristiina; Thomas, David B.

doi:10.1158/1055-9965.epi-07-0368

Cited by 46 publications

(33 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To minimize the attenuation of risk estimates derived from random measurement errors, the authors matched fasting time between cases and controls [37]. In addition, another recently published Chinese case-control study showed a significant breast cancer risk reduction in women with high plasma levels of genistein (OR 0.26, 95% CI 0.13-0.50) [38].…”

Section: High Isoflavone Consumption and Breast Cancer Riskmentioning

confidence: 99%

Isoflavones – Mechanism of Action and Impact on Breast Cancer Risk

Stubert¹,

Gerber²

2009

Breast Care

View full text Add to dashboard Cite

Isoflavones are plant-derived substances with weak estrogenic effects. Asian populations are high consumers of soy products which are rich in isoflavones. The lower breast cancer incidence in Asian women compared with Western women has been associated with the possibility of a preventive isoflavone effect on cancer risk. The aim of this review is to give an overview of current research data on the influence of isoflavones on the risk of primary breast cancer development as well as the risk of recurrence in breast cancer patients. Despite inconsistencies in the available data, an inverse correlation between isoflavone intake and risk of breast cancer is likely. However, a negative impact on breast cancer disease, especially on hormone receptor-positive tumors, cannot be excluded at present.

show abstract

Section: High Isoflavone Consumption and Breast Cancer Riskmentioning

confidence: 99%

Isoflavones – Mechanism of Action and Impact on Breast Cancer Risk

Stubert¹,

Gerber²

2009

Breast Care

View full text Add to dashboard Cite

show abstract

“…Genistein (4,5,7-trihydroxyisoflavone) has been identified as the predominant isoflavone in soybean enriched foods which comprises a significant portion of the Asian diet, and provides 10% of the total per capita protein intake in Japan and China. A recent study among women in Shanghai, China found that plasma isoflavone concentration were inversely associated with the risk of non-proliferative and proliferative benign fibrocystic conditions as well as breast cancer [1]. In parallel, relatively high levels of soy isoflavones have been found in the serum, urine and prostatic fluid of Asian men who consume a soy rich diet possibly contributing in lowering the incidence of prostate cancer [2;3].…”

Section: Introductionmentioning

confidence: 99%

Multi-targeted therapy of cancer by genistein

Banerjee¹,

Li²,

Wang³

et al. 2008

Cancer Letters

560

383

View full text Add to dashboard Cite

Soy isoflavones have been identified as dietary components having an important role in reducing the incidence of breast and prostate cancers in Asian countries. Genistein, the predominant isoflavone found in soy products, has been shown to inhibit the carcinogenesis in animal models. There is a growing body of experimental evidence showing that the inhibition of human cancer cell growth by genisteinis mediated via the modulation of genes that are related to the control of cell cycle and apoptosis. It has been shown that genistein inhibits the activation of NF-κB and Akt signaling pathways, both of which are known to maintain a homeostatic balance between cell survival and apoptosis. Moreover, genistein antagonizes estrogen-and androgen-mediated signaling pathways in the processes of carcinogenesis. Furthermore, genistein has been found to have antioxidant properties, and shown to be a potent inhibitor of angiogenesis and metastasis. Taken together, both in vivo and in vitro studies have clearly shown that genistein, one of the major soy isoflavones, is a promising agent for cancer chemoprevention and further suggest that it could be an adjunct to cancer therapy by virtue of its effects on reversing radioresistance and chemoresistance. In this review, we attempt to provide evidence for these preventive and therapeutic effects of genistein in a succinct manner highlighting comprehensive state-of-the-art knowledge regarding its multi-targeted biological and molecular effects in cancer cells.

show abstract

“…Strikingly, a randomized, double-blinded, placebo-controlled study of 383 women indicated that the magnitude of the protective association was similar in western populations despite their markedly different levels of intake compared to Asian women [25]. Intake of genistein may protect against the development of breast and prostate cancer and did not cause the development of new, estrogen-dependent breast or reproductive tissue cancers [20, 26]. In addition to its chemoprevention effect on breast and prostate cancer, genistein can be selectively cytotoxic to neoplastic and preneoplastic cells as well as lung and pancreatic cancer cell lines in vitro [27–29].…”

Section: Introductionmentioning

confidence: 99%

Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME

Yang¹,

Kulkarni²,

Zhu³

et al. 2012

ACAMC

197

123

View full text Add to dashboard Cite

Genistein, one of the most active natural flavonoids, exerts various biological effects including chemoprevention, antioxidation, antiproliferation and anticancer. More than 30 clinical trials of genistein with various disease indications have been conducted to evaluate its clinical efficacy. Based on many animals and human pharmacokinetic studies, it is well known that the most challenge issue for developing genistein as a chemoprevention agent is the low oral bioavailability, which may be the major reason relating to its ambiguous therapeutic effects and large interindividual variations in clinical trials. In order to better correlate pharmacokinetic to pharmacodynamics results in animals and clinical studies, an in-depth understanding of pharmacokinetic behavior of genistein and its ADME properties are needed. Numerous in vitro/in vivo ADME studies had been conducted to reveal the main factors contributing to the low oral bioavailability of genistein. Therefore, this review focuses on summarizing the most recent progress on mechanistic studies of genistein ADME and provides a systemic view of these processes to explain genistein pharmacokinetic behaviors in vivo. The better understanding of genistein ADME property may lead to development of proper strategy to improve genistein oral bioavailability via mechanism-based approaches.

show abstract

Plasma Isoflavones and Fibrocystic Breast Conditions and Breast Cancer Among Women in Shanghai, China

Cited by 46 publications

References 30 publications

Isoflavones – Mechanism of Action and Impact on Breast Cancer Risk

Isoflavones – Mechanism of Action and Impact on Breast Cancer Risk

Multi-targeted therapy of cancer by genistein

Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME

Contact Info

Product

Resources

About